aldoxorubicin
Sponsors
ImmunityBio, Inc., CytRx
Conditions
Advanced Solid TumorAdvanced Solid TumorsMetastatic Small Cell Lung CancerMetastatic Solid TumorsMetastatic, Locally Advanced or Unresectable Soft Tissue SarcomaNon Small Cell Lung CancerSarcoma
Phase 1
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
CompletedNCT01673438
Start: 2012-07-31End: 2014-04-30Updated: 2022-02-10
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
CompletedNCT01706835
Start: 2012-10-31End: 2014-12-31Updated: 2022-02-10
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
CompletedNCT02235688
Start: 2014-08-31End: 2017-01-31Target: 30Updated: 2022-02-10
Phase 2
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
CompletedNCT02200757
Start: 2015-04-20End: 2017-05-15Updated: 2024-06-25
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
WithdrawnNCT03574649
Start: 2018-06-30End: 2018-08-22Updated: 2025-02-21